Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02538627 · Merrimack Pharmaceuticals · PHASE1 · terminated · last registry update 2017-09-05 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Merrimack Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB3 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-01-23Results posted on the registry: Daiichi Sankyo, Patritumab + Erlotinib (NCT02134015)
- 2018-01-23Also stopped (terminated): Daiichi Sankyo, Patritumab + Erlotinib (NCT02134015)
- 2017-04-24Also stopped (withdrawn): SWOG Cancer Research Network, docetaxel + vandetanib (NCT00937417)
- 2016-09-08Results posted on the registry: Merrimack Pharmaceuticals, MM-121 + Irinotecan (NCT01451632)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision